2nd International
Workshop on Vaccine Adjuvants and GlycoConjugates
Varadero,
Cuba April 10th-16th, 2004
Organized by
-
Cuban Society for Immunology (CSI)
and Latin American Association of Immunology (ALAI)
-
With the cooperation (as per January
15th, 2004) of
-
Finlay Institute, Center for Genetic
Engineering and Biotechnology (CIGB), Center of Molecular
Immunology, House of SofTware TEDNUS, Amersham Biosciences,
EGREM
Invitation
The International Workshop on Vaccine
Adjuvants and Glycoconjugates is organized to discuss
update aspects concerning the development of Adjuvants
and Glycoconjugates of importance in human and veterinary
vaccines.
The Keynotes Address, Interactive Workshops,
and Poster Exhibits will give an unique opportunity for
discussion and cooperation to all Colleagues from Academia,
Industry, Governmental Services, and Research Institutes
who are interested in sharing last experiences in these
field.
We look forward to the great opportunity
of welcoming you warmly at our International Workshop
on Vaccine Adjuvants and Glycoconjugates in Cuba.
President Adjuvant2004
Finlay Institute
Mark your calendar for 2nd International
Workshop on Vaccine Adjuvants and Glycoconjugates in Varadero,
Cuba, April 11.
Call for Abstracts
The Organizers will put in the web in
advance the scientific program with Keynotes Address from
well-known specialist invited and with some topics from
submitted abstracts selected. When sending the abstract,
please indicate the Topic in which you would like to be
included. Oral and Poster presentations should be clearly
indicated. Cubamagica will be reserved the right of choosing
oral presentation. English is the official language of
the Workshop. Cubamagicaa will inform authors via e-mail
about
the acceptance of presentations, not later than one month
after the reception of the abstract. The program will
be printed. For this reason, we encourage to provide a
250 - word abstract, as soon as possible. New Deadline
for oral presentations and posters is February 10th, 2004.
Authors should provide their abstract by E-mail (cubamagica@cubamagica.com)
in Word format. Please capitalize the title of the abstract,
then type in the author’s name(s), institution(s),
city and country. The abstract should contain the purpose
of the study, method used, essential results and conclusion.
It should by typed in the 16 cm width by 9 cm height format.
Indicate with * the presenter’s name. Workshop program
will be published on the web site. The Workshop program
will be also distributed with documentation on site. The
presenter should provide his full name, address of institution,
e-mail, fax and telephone numbers. Facilities will be
available in the workshop sessions for computer assisted
presentations.
Registration Fees
All delegates should pay in advance
(except delegates of USA) the registration fees. The delegates
of USA will pay cash during the event and it will be consider
as early registration. Payment will ensure accommodation
at discount price, access to all scientific activities,
related documentation with program and abstracts booklet,
welcome cocktail and closer activity.
Please fill up the registration form
and send it by E-mail. The Workshop organizers policy
is to maintain registration fees as low as possible to
encourage the attendance. Deadline for early registration
is February 15th, 2004:Private Sector (US$ 350), Academic
and Governmental Sectors (US$ 250), Students (US$ 100)
and late registration should paid: Private Sector (US$
400), Academic and Governmental Sector (US$ 300), Students
(US$ 150). Accompanying person registration (US$ 150).
Letter of Invitation
The Organizers will provide a letter
of invitation to delegates, if requested, to help in obtaining
funds or visas. Invitation does not imply any financial
support from the Workshop Organizing Committee. The letter
will be sent after confirmation of registration.
2nd International Workshop on Vaccine Adjuvants and GlycoConjugates
Workshop Registration Form
Please complete and return as soon as possible to the
Workshop Office by e-mail: cubamagica@cubamagica.com
Name: Title/Function:Organization/Company: Address:City:
Country:Postal code: Fax: E-mail: Presenting theme: Topic:My
organisation is interested in sponsoring Adjuvant2004:
YES____ NO____Please send me details of exhibition:I wish
to be placed on the mailing list to receive further information
on Adjuvant2004:Please send me a set of Adjuvant2004 materials:
-
April 11
Depart from Havana (13:00)
Arrival and Registration (15:00)
Welcome Ceremony,
Opening Conference and Cocktail (17:30 - 21:00)
-
April 12 to 14
Keynotes Address (8:30 - 9:15)
Symposiums (9.15 - 16:00)
Poster Sessions discussion (evening 13th)
-
April 15
Keynotes Address (8:30 - 9:15)
Symposiums (9.15 - 12:00)
Conclusions and Closing Ceremony (12:00)
-
Oral/Nasal/Dermal delivery methods
for vaccines
-
Vaccines adjuvants already in or
very close to entering clinical trials
-
Adjuvants that induce CTL responses
-
Painless delivery system
-
Glycoconjugates as vaccines
-
Mechanism of Action of Adjuvants
-
Dendritic cells as arget of Adjuvants
-
Polysaccharide Adjuvants
-
Adjuvants for DNA Vaccines
-
Adjuvants for Parasitic Diseases
-
Procedures for the testing of new
Adjuvants
-
Cytokines and other Immunomodulators
-
Oil-based Adjuvants
-
Carrier Proteins
-
Tumor Vaccines Adjuvants
-
Allergic Vaccines Adjuvants
-
Glycoconjugates Vaccines
-
Quality Control and Regulatory issues
for Adjuvants and Glycoconjugates
Confirmed Keynotes Address
-
Author Title
Agustin Lage, Cuba To be confirmed
Gordon Dugan, UK Adjuvanting New Vaccines: Learning
from Pathogens.
Stanley Davis, UK The Use of Soluble Polymers and Polymer
Microparticles to Provide Improved Vaccine. Responses
after Parenteral and Mucosal Administration.
Rino Rappuoli, Italy Reverse Vaccinology.
-
Paineless Vaccines
Chairman: Co-Chairman: Oliver Pérez
Author Title
Ulf Schröder, Sweden Eurocine™ adjuvants
for nasal vaccines.
H. Oya Alpar, UK Title pending
Laura Bracci, Italy Type I IFN as a vaccine adjuvant
for both systemic and mucosal vaccination against influenza
virus.
Oliver Pérez, Cuba Proteliposome derived Cochleate
as adjuvant vaccine.
-
The potential of toxins and lectins
in vaccine delivery.
Chairman: Ed Lavelle Co-Chairman: Julio A. Balboa
Author Title
Ed Lavelle, Ireland Plant lectins as mucosal vaccine
adjuvants.
Gregory Russell-Jones, Australia The use of intestinal
binding proteins as carriers for oral vaccines.
Maria Teresa De Magistris, Italy Bacterial enterotoxins
as mucosal adjuvants and their effects on cells of the
immune system.
Tim Hirst, UK Towards the development of a CD8+ T-cell
adjuvant.
Cecil Czerkinsky, France Bacterial adjuvants for transepithelial
vaccination.
-
Mucosal immunomodulators and adjuvants
Chairman: Ali M. Harandi Co-Chairman: Gustavo Bracho
Author Title
Ali M. Harandi, Sweden CpG DNA as potent inducer of
mucosal immunity: Implications for immunoprophylaxis
and immunotherapy of mucosal infections
Gustavo Bracho, Cuba Proteoliposome derived cochleates
as mucosal adjuvant.
-
Cellular Adjuvants
Chairman: Nikolai Petrovsky Co-Chairman: Tamara Rodríguez
Author Title
Nikolai Petrovsky, Australia Why has it been so difficult
to develop human-approved adjuvants with the ability
to stimulate both antibody and cellular immune responses;
the ADVAX© experience.
Vanessa Durand, UK IFN-alfa/beta-Dependent cross-priming
induced by specific toll-like receptor agonists.
Jan Wilschut, The Netherlands Virosomes in influenza
vaccine development.
Tamara Rodríguez, Cuba Bacterial derived Proteoliposome
as ideal delivery system and cellular adjuvant.
Andy Heath, UK Antibodies against cell surface antigens
as very potent immunological adjuvants
-
Adjuvants, immunotherapy and prevention
of the allergies
Chairman: Co-Chairman: Alexis Labrada
Author Title
Alexis Labrada, Cuba The state of the art in developing
allergen vaccines in Cuba: Prospects of novel adjuvanted
vaccines
Oliver Pérez, Cuba Bacterial derived Proteoliposome
for allergy vaccine.
Lesly Calderón, Cuba Modulation of the specific
allergic response by mite allergens entrapped into Liposomes
Ilonka Estruch, Cuba Present and future of the immunotherapy
in the allergic patient's treatment
-
Clinical Impact of glycoconjugate
vaccine now and in the near future.
Chairman: Steven Black Co-Chairman: Osmir Cabrera
Author Title
Steven Black, USA The Impact of Pneumococcal Conjugate
Vaccines on Invasive Disease.
Henry Shinefield, USA Staphylococcal Conjugate Vaccine.
Keith Klugman, USA The Impact of Pneumococcal Conjugate
Vaccine on Pneumonia and ALRI.
Lisa Danzig, USA Impact of meningococcal glycoconjugate
vaccines.
Mathu Santosham, USA Haemophilus Influenza Type b Conjugate
Vaccines.
Vicente Vérez, Cuba The First Human Vaccine with
a Synthetic Antigen.
-
Adjuvants for Cancer vaccine
Chairman: Co-Chairman: Circe Mesa
Author Title
Circe Mesa, Cuba To be confirmed
Luis Enrique Fernández, Cuba To be confirmed
-
Adjuvant Production
Chairman: Co-Chairman: Domingo González
Author Title
Ricardo San Martin, Chile Production of quillaja (Quillaja
saponaria MOLINA) saponins as vaccine adjuvants.
Luuk A.Th. Hilgers, The Netherlands Sucrose Fatty Acid
Sulphate Esters as novel vaccines adjuvant.
Caridad Zayas, Cuba Scale up of Proteoliposome derived
Cochleate.
Domingo González, Cuba To be confirmed
- Regulatory aspects of Adjuvants and Conjugates
Author Title
Dorothea Sesardic, UK Regulatory considerations on new
adjuvants and delivery systems
|
|
Otros países diferente de Colombia
y El Salvador, interesados en recibir más
información y coordinación de viaje, deben pagar
$ 100.00 USD por persona interesada en
el evento previo a cualquier información nueva o coordinación
o servicio. Este pago se hace a oficina de Cubamagica de El Salvador,
si la persona viaja se le incluye estos $ 100.00 USD como abono
a su alojamiento en Cuba, si no viaja se tomará como pago
por los servicios prestados y no habrá devolución
por ningún concepto.
|
|
Leer Importante: Les informamos que en CUBA ya no se
usa el dolar estadounidense como moneda, su lugar lo ocupo el PESO CONVERTIBLE
cubano.
Por todo lo anterior, le sugerimos que venga a Cuba con euros, libras
esterlinas, dolares canadienses o francos suizos y los cambien a PESO
CONVERTIBLE cubano en el propio aeropuerto, en el hotel donde se hospedara
o en los bancos de cualquier ciudad.
(1 PESO CONVERTIBLE cubano = 1.20 USA dolar)
Si usted viene a Cuba con dolares de Estados Unidos al cambiarlos
al PESO CONVERTIBLE cubano tendra un impuesto del 18%,
las otras monedas tendran un impuesto del 8%.
Participación en el evento:
Las personas que desean participar en el evento, comuniquese con nosotros
a:cubamagica@cubamagica.com
| Si desea más información sobre este evento,
alojamiento, transporte, cuota de inscripción, etc
favor contactar a cubamagica@cubamagica.com,
será un placer atenderle.
Cubamagica.com
Telefax.: (503) 240-0369 / 240-0365
E-mail: cubamagica@cubamagica.com |
|
Ayuda o asistencia: Si la necesita envie
un e-mail aquí click
Seguros: Cada día de estancia en Cuba cuesta $ 5.00. Para
conocer el precio de su seguro multiplique los días de su estancia
en Cuba por los $5.00. Click aquí
Trámites migratorios:
* Para Viajar a Cuba solo necesita pasaporte en regla
* La visa o tarjeta de turista la extiende la agencia de viajes o la línea
aérea a la que le compre el boleto aéreo (si tiene dificultades
para adquirir la visa o tarjeta de turismo, Cubamagica.com se la
puede enviar por correo aéreo, estas tienen un precio de $ 25.00
dólares americanos cada una. Este precio no incluye el costo del
envío).
Otros servicios: Tours opcionales, y
seguro de viaje (click más servicios)
Nota: Usted puede combinar su estancia en Cuba por motivo de este
evento, con otras opciones: turísticas, médicas, negocios,
educativas, profesionales, etc.(vea página
inicial de Cubamagica.com)
Le
recomendamos visitar la página principal de Cubamagica.com |
|
|
|
Casa
Matriz o principal :